Emergent BioSolutions (EBS), Integrated BioTherapeutics Enter Equine-Based Hyperimmunoglobulin Licensing Agreement
Go back to Emergent BioSolutions (EBS), Integrated BioTherapeutics Enter Equine-Based Hyperimmunoglobulin Licensing Agreement| EMERGENT BIOSOLUTIONS, Inc. (NYSE: EBS) | Delayed: 2.29 +0.13 (6.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.16 | 52 Week High | $44.38 | |||
| Open | $2.15 | 52 Week Low | $24.47 | |||
| Day High | $2.36 | P/E | 114.50 | |||
| Day Low | $2.13 | EPS | $0.02 | |||
| Volume | 860,990 | |||||
